Deuterium Capital Management LLC Invests $381,000 in Nektar Therapeutics (NASDAQ:NKTR)

Key Points

• Deuterium Capital Management LLC invested $381,000 in Nektar Therapeutics, acquiring 560,235 shares, which now constitutes 0.8% of its portfolio.
• Nektar Therapeutics reported a loss of ($3.30) earnings per share, missing estimates, and had negative revenue of $10.46 million for the last quarter.
• Wall Street analysts have varied ratings on Nektar, with the consensus being a "Moderate Buy" and a target price of $88.33 per share.

Deuterium Capital Management LLC bought a new position in Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 560,235 shares of the biopharmaceutical company's stock, valued at approximately $381,000. Nektar Therapeutics comprises 0.8% of Deuterium Capital Management LLC's holdings, making the stock its 14th largest holding. Deuterium Capital Management LLC owned approximately 0.30% of Nektar Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in NKTR. Mackenzie Financial Corp raised its holdings in Nektar Therapeutics by 253.1% during the 1st quarter. Mackenzie Financial Corp now owns 1,658,745 shares of the biopharmaceutical company's stock valued at $1,128,000 after acquiring an additional 1,188,976 shares during the period. CWM LLC raised its holdings in Nektar Therapeutics by 4,544.5% during the 1st quarter. CWM LLC now owns 105,524 shares of the biopharmaceutical company's stock valued at $72,000 after acquiring an additional 103,252 shares during the period. Cerity Partners LLC bought a new stake in Nektar Therapeutics during the 1st quarter valued at $52,000. 49 Wealth Management LLC bought a new stake in Nektar Therapeutics during the 1st quarter valued at $56,000. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in Nektar Therapeutics during the 1st quarter valued at $41,000. 75.88% of the stock is currently owned by hedge funds and other institutional investors.

Nektar Therapeutics Trading Down 5.4%

NKTR opened at $23.65 on Tuesday. Nektar Therapeutics has a 1-year low of $6.45 and a 1-year high of $37.38. The company has a market capitalization of $293.50 million, a PE ratio of -2.46 and a beta of 0.94. The firm's 50 day simple moving average is $17.44 and its two-hundred day simple moving average is $13.59.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) earnings per share for the quarter, missing the consensus estimate of ($2.70) by ($0.60). Nektar Therapeutics had a negative return on equity of 329.54% and a negative net margin of 152.49%. The business had revenue of $10.46 million during the quarter, compared to the consensus estimate of $15.61 million. During the same quarter in the previous year, the business posted ($2.70) earnings per share. Equities analysts forecast that Nektar Therapeutics will post -0.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on NKTR. Wall Street Zen lowered shares of Nektar Therapeutics from a "hold" rating to a "sell" rating in a research report on Wednesday, May 14th. William Blair reiterated a "market perform" rating on shares of Nektar Therapeutics in a research report on Monday, May 12th. BTIG Research lifted their target price on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, June 24th. HC Wainwright lifted their target price on shares of Nektar Therapeutics to $120.00 and gave the stock a "buy" rating in a research report on Tuesday, June 24th. Finally, Jefferies Financial Group upgraded shares of Nektar Therapeutics from a "hold" rating to a "buy" rating and lifted their target price for the stock from $15.00 to $30.00 in a research report on Friday, April 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, Nektar Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $88.33.

Nektar Therapeutics Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.